Company profile · Vilnius, Lithuania

Biomatter

Generative Protein Design, Enzyme Engineering, Computational Biology, and AI-Driven Discovery · AI-enabled protein-discovery platform

AI-protein-design node connecting generative biology, enzyme engineering, and Lithuanian deep-tech commercialization.

Lead
Laurynas Karpus (verified ↗)
Address
Business West Stadium, Rinktines str. 5-101, LT-09234 Vilnius, Lithuania (source ↗)
Compliance
GLP
Last reviewed
15 Mar 2026 (3mo ago)
Scale
AI-enabled protein-discovery platform
Capabilities
Protein design · Enzyme engineering · Computational biology
Founded
2018
Headcount
11-50
LinkedIn
Company page (open ↗)
Site and address
Clinical profileSTATUS: VERIFIED MARCH 2026

Laurynas Karpus

Chief Executive Officer and Co-Founder

Check official leadership source
Full addressBusiness West Stadium, Rinktines str. 5-101, LT-09234 Vilnius, Lithuania
Site coordinates54.694008, 25.288911
Review cycleMay 2026
Physical site source

Official Biomatter contact-information page listing Business West Stadium, Rinktines str. 5-101, Vilnius.

Open source
Operating profile

AI-enabled protein-discovery platform

Vilnius, Lithuania. Generative Protein Design, Enzyme Engineering, Computational Biology, and AI-Driven Discovery. Review completed on 15 Mar 2026.

2026 technical specializationGenerative Protein Design, Enzyme Engineering, Computational Biology, and AI-Driven Discovery
Core capabilities
Protein designEnzyme engineeringComputational biologyAI discovery workflows
Governance

Lithuanian and EU biotech discovery governance framework

Computational-biology platform governance, Drug-discovery quality systems

Editorial note

Generative Protein Design, Enzyme Engineering, Computational Biology, and AI-Driven Discovery

AI-protein-design node connecting generative biology, enzyme engineering, and Lithuanian deep-tech commercialization.

Editorial note

Biomatter moves into the verified layer with a current official executive record and a differentiated AI-protein-design platform.

FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026Last reviewed: 15 March 2026
Capabilities

Core capabilities

Primary declared technical activities and areas of operating focus.

Protein design
Enzyme engineering
Computational biology
AI discovery workflows
Verification source dossier

Verification source dossier

Official source set used to support leadership, physical-site, certification, and watch-note evidence.

Leadership evidenceBiomatter official team page confirming Laurynas Karpus as CEO and co-founder.Source origin: biomatter.aiOpen source
Supporting evidenceBiomatter official company surface describing the generative-protein-design platform.Source origin: biomatter.aiOpen source
Physical-site evidenceOfficial Biomatter contact-information page listing Business West Stadium, Rinktines str. 5-101, Vilnius.Source origin: biomatter.aiOpen source
Infrastructure

Declared infrastructure

Protein-design compute platform
Enzyme-engineering workflows
Integrated discovery environment
Regulatory posture

Quality system coverage

GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.

GMP
REVIEW IN PROGRESS 2026
GLP
VERIFIED ACTIVE 2026
ISO-13485
REVIEW IN PROGRESS 2026
FDA-Inspected
REVIEW IN PROGRESS 2026
Verification history

Verification history

15 Mar 2026: Executive identity confirmed via official management disclosure.
15 Mar 2026: Full trust review completed.
FAQ

Frequently asked questions

Where is Biomatter located?
Biomatter operates from Business West Stadium, Rinktines str. 5-101, LT-09234 Vilnius, Lithuania, Vilnius, Lithuania.
Who runs Biomatter?
Biomatter is led by Laurynas Karpus, Chief Executive Officer and Co-Founder. Verified 15 Mar 2026.
What does Biomatter do?
AI-protein-design node connecting generative biology, enzyme engineering, and Lithuanian deep-tech commercialization. Core capabilities: Protein design, Enzyme engineering, Computational biology, AI discovery workflows.
Editorial context

Related technical briefs

Briefs that name Vilnius as a covered market or city.